Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2068MR)

This product GTTS-WQ2068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2068MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2247MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ7816MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ2499MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ3730MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ14026MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ7172MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ10849MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ9788MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW